Home › Breast Cancer › Illinois
Breast Cancer clinical trials in Illinois
81 studies for Breast Cancer are looking for participants at sites in Illinois.
Cities in Illinois
- Chicago59 studies
- Evanston13 studies
- Waukegan12 studies
- Champaign11 studies
- Naperville10 studies
- Cicero10 studies
- Springfield8 studies
- Peoria8 studies
- Decatur8 studies
- Aurora7 studies
- Carbondale7 studies
- Arlington Heights6 studies
- North Peoria5 studies
- Elgin5 studies
- Danville5 studies
- Galesburg5 studies
- Rockford5 studies
- Charleston5 studies
- Joliet5 studies
- Bloomington5 studies
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- University of Illinois at Chicago, Chicago
- NorthShore University Health System - Evanston Hospital, Evanston
- Duly Health and Care, Lisle
- and 2 more
RecruitingPhase 1
Ages 18 to 55 · Women · Updated Nov 12, 2026 · NCT07310420Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Orchard Healthcare Research Inc. ( Site 0006), Skokie
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06797635S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- John H Stroger Jr Hospital of Cook County, Chicago
- Decatur Memorial Hospital, Decatur
- Loyola University Medical Center, Maywood
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03418961A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- University of Illinois Hospital & Health Sciences System, Chicago
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06827236A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Southern Illinois Hospital Services ( Site 9554), Carterville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06966700ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- City of Hope Chicago, Zion
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT07007559BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
- University of Illinois Cancer Center, Chicago
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT04891068Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
- University of Illinois, Chicago
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT06169371A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- City of Hope® Cancer Center Chicago, Zion
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT03424005Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Orchard Healthcare Research Inc.- Skokie, Skokie
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06324357Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Northwestern University, Chicago
Recruiting
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07214532Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Northwestern University, Chicago
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT05315700Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Rush University Medical Center, Chicago
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06982521A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- City of Hope, Chicago, Chicago
- Northwestern Memorial Hospital, Chicago
- University of Illinois at Chicago, Chicago
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07174336A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Cancer Care Specialists of Central Illinois, O'Fallon
- Springfield Clinic, Springfield
- Carle Cancer Center, Urbana
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06790693E-Mindfulness Approaches for Living After Breast Cancer
- Northwest Community Hospital, Arlington Heights
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- and 55 more
RecruitingPhase 3
Ages 18 to 50 · All sexes · Updated Nov 4, 2026 · NCT06748222A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- City of Hope, Chicago, Chicago
RecruitingPhase 2
Ages 18 and older · Women · Updated Nov 4, 2026 · NCT07287098Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- OSF Saint Anthony's Health Center, Alton
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- and 52 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- OSF Saint Anthony's Health Center, Alton
- Rush-Copley Medical Center, Aurora
- Advocate Outpatient Center - Aurora, Aurora
- and 45 more
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06418204Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- OSF Saint Anthony's Health Center, Alton
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- and 83 more
RecruitingPhase 3
Ages 18 to 60 · Women · Updated Nov 4, 2026 · NCT05879926ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Cancer Care Specialists, Decatur
- Cancer Care Specialists of Illinois, O'Fallon
- Carle Foundation Hospital d/b/a Carle Cancer Center, Urbana
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT07173751Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
- Northshore University Health System, Evanston
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT05974150A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- The University of Chicago Medical Center, Chicago
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT07102381A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- City of Hope, Chicago, Zion
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT07109726EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
- Rush Cancer Center, Chicago
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06401421A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- University of Illinois Cancer Center, Chicago
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06172478A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- City of Hope® Cancer Center Chicago, Zion
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT07100106Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss
- Carle Health, Urbana
Recruiting
Ages 21 and older · Women · Updated Oct 22, 2026 · NCT05484973A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Evanston
RecruitingPhase 3
Ages 18 to 130 · All sexes · Updated Oct 19, 2026 · NCT07647328A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Endeavor Health Cancer Institute at Swedish Hospital, Nancy W. Knowles Cancer Center, Elmhurst
- Prime Saint Francis-Infusion Services Evanston, Evanston
- Hope and Healing Clinical Research LLC, Hinsdale
- and 8 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT07062965Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
- City of Hope - Chicago, Zion
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06293898A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Rush University Medical Center ( Site 0079), Chicago
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06312176Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- Carle Cancer Center, Urbana
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT05386108Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, Chicago
RecruitingPhase 1/2
Ages 18 to 130 · All sexes · Updated Oct 5, 2026 · NCT05417594A Study of PHST001 in Advanced Solid Tumors
- University of Chicago Medical Center, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT06840886A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- University of Illinois Cancer Center, Chicago
- The University of Chicago, Chicago
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06369285PRE-ISPY Phase I/II Oncology Platform Program
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
- UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital, New Lenox
- UChicago Medicine Orland Park, Orland Park
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT05868226Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- Northwestern Medicine Chicago Proton Center, Warrenville
RecruitingPhase 2
Ages 50 and older · Women · Updated Sep 29, 2026 · NCT01766297Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
Recruiting
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07553234A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Chicago
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06103864From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.